Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for detecting BCMACAR affinity

An affinity, positive cell technology, applied in the field of cell therapy, can solve the problems of low expression and no expression of B cell marker proteins

Pending Publication Date: 2020-06-30
HRAIN BIOTECHNOLOGY CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, abnormal plasma cells in MM hardly express CD19, and most of the B cell marker proteins express little or no expression. Therefore, CAR-T therapy for MM needs to find new targets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting BCMACAR affinity
  • Method for detecting BCMACAR affinity
  • Method for detecting BCMACAR affinity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Binding affinity of BCMA IgG to BCMA positive cell lines

[0021] The specific steps are: use the expressed and purified Anti-human BCMA IgG (clone number: C11D5.3) prepared by our company, set the initial concentration to 100ug / ml, and then dilute 7 points according to 1:3 gradient, respectively with 3× 10 5 The human BCMA-positive cell line MM.1S and H929 were co-incubated (see Table 1 for specific groups), and then the flow cytometry antibody PE-anti human IgG-Fc was used to detect the BCMA IgG bound to the target cells, and its fluorescence was detected by flow cytometry strength and judge binding affinity.

[0022] Table 1 Grouping of BCMA IgG binding affinity test to BCMA-positive cell lines

[0023]

[0024] Example results see figure 1 , figure 2 . Among them, the EC50 of MM.1S binding affinity to BCMA IgG is 37nM, and that of H929 reaches 57nM.

Embodiment 2

[0025] Embodiment 2: ELISA detection of binding affinity between BCMA IgG and BCMA

[0026] The specific steps are as follows: the test first uses 2 μg / ml Human BCMA protein to coat the ELISA plate, washes off the free protein after 1 hour, and then dilutes 8 concentration gradients with the purified Anti-human BCMA IgG 2ug / ml 1:3 made by our company. Incubate at 37°C for 1 hour, wash off excess antibody, and then use secondary antibody Biotin Goat anti mouse F(ab) in sequence 2 Incubate with the third antibody Streptavidin-HRP at 37°C for 1 hour, and finally develop the color, and read the OD450 / 620 value on a microplate reader.

[0027] The results of this example are shown in figure 1 , figure 2 . Coat the plate with excess Human BCMA-Fc protein, then incubate with 8 concentrations of Anti-human BCMA IgG with an initial concentration of 2ug / ml and 1:3 gradient dilution, and detect its binding affinity by ELISA, with an EC50 value of 1.2 nM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for detecting BCMACAR affinity. The method mainly comprises the following steps: (1) detecting the binding affinity of BCMA IgG and a BCMA positive cell line; 2) detecting BCMA IgG and BCMA binding affinity ELISA. The method can effectively determine the affinity of the BCMACAR antibody, and has the advantages of safety, high sensitivity, good repeatability, stableand reliable detection result and the like.

Description

technical field [0001] The invention belongs to the field of cell therapy, and in particular relates to a BCMA CAR affinity detection method. Background technique [0002] Chimeric Antigen Receptor-T cell (CAR-T) T cells refer to T cells that can recognize specific target antigens in an unrestricted manner by MHC after genetic modification, and continuously activate and expand T cells. In 2012, the annual meeting of the International Society for Cell Therapy pointed out that biological immune cell therapy has become the fourth means of tumor treatment besides surgery, radiotherapy, and chemotherapy, and will become a must-have means for future tumor treatment. CAR-T cell reinfusion therapy is the most clear and effective form of immunotherapy in current tumor treatment. A large number of studies have shown that CAR-T cells can effectively recognize tumor antigens, induce specific anti-tumor immune responses, and significantly improve the survival of patients. [0003] Chim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/574G01N33/58G01N33/50G01N15/14
CPCG01N33/6854G01N33/57484G01N33/582G01N33/505G01N33/5052G01N15/14
Inventor 王海鹰王赛赛
Owner HRAIN BIOTECHNOLOGY CO LTD